H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015 Is Released H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015 Summary Global Markets Direct s, H5N1 Infection (Avian Influenza) - Pipeline Review, H2 2015, provides an overview of the H5N1 Infection (Avian Influenza)s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for H5N1 Infection (Avian Influenza), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for H5N1 Infection (Avian Influenza) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for H5N1 Infection (Avian Influenza) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the H5N1 Infection (Avian Influenza) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the H5N1 Infection (Avian Influenza) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics - Develop and design inlicensing and out-licensing strategies by identifying prospective partners with the most attractive 1
projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173366/h5n1infection-avian-influenza-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173366/h5n1-infection-avian-influenza-pipeline-review-h2-2015 Table of Contents
Introduction 9 Global Markets Direct Report Coverage 9 H5N1 Infection (Avian Influenza) Overview 10 Therapeutics Development 11 Pipeline Products for H5N1 Infection (Avian Influenza) - Overview 11 Pipeline Products for H5N1 Infection (Avian Influenza) - Comparative Analysis 12 H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies 13 H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes 18 H5N1 Infection (Avian Influenza) - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 H5N1 Infection (Avian Influenza) - Products under Development by Companies 22 H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes 27 H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development 28 Akshaya Bio Inc. 28 Altimmune, Inc. 29 Antigen Express, Inc. 30 Aphios Corporation 31 Aprogen, Inc. 32 BioDiem Ltd 33 2
BiondVax Pharmaceuticals Ltd. 34 CEL-SCI Corporation 35 Cocrystal Pharma, Inc. 36 CSL Limited 37 Daiichi Sankyo Company, Limited 38 Emergent BioSolutions Inc. 39 Gemmus Pharma Inc. 40 GlaxoSmithKline Plc 41 Green Cross Corporation 42 Hemispherx Biopharma, Inc. 43 iBio, Inc. 44 Immunovaccine, Inc. 45 Inovio Pharmaceuticals, Inc. 46 Johnson & Johnson 47 Kineta, Inc. 48 Medicago Inc. 49 MedImmune, LLC 50 Microbiotix, Inc. 51 Microgen Scientific Industrial Company for Immunobiological Medicines 52 Myelo Therapeutics GmbH 53 NanoBio Corporation 54 Nanotherapeutics, Inc. 55 NanoViricides, Inc. 56 NewLink Genetics Corporation 57 OPKO Health, Inc. 58 PaxVax, Inc. 59
3
PDS Biotechnology Corporation 60 PeptiDream Inc. 61 Protein Sciences Corporation 62 Shionogi & Co., Ltd. 63 Sirnaomics, Inc. 64 Takeda Pharmaceutical Company Limited 65 TechnoVax, Inc. 66 Theraclone Sciences, Inc. 67 Vaxine Pty Ltd 68 VaxInnate Corporation 69 H5N1 Infection (Avian Influenza) - Therapeutics Assessment 70 Assessment by Monotherapy Products 70 Assessment by Combination Products 71 Assessment by Target 72 Assessment by Mechanism of Action 74 Assessment by Route of Administration 76 Assessment by Molecule Type 78 Drug Profiles 80 A-06 - Drug Profile 80 AE-443p - Drug Profile 81 Alferon LDO - Drug Profile 83 AP-302 - Drug Profile 84 APP-0205 - Drug Profile 85 APP-309 - Drug Profile 86 AT-301 - Drug Profile 87 CEL-1000 - Drug Profile 88 DP-C005 - Drug Profile 90 4
FBF-001 - Drug Profile 91 FDX-000 - Drug Profile 92 Gamma-Flu - Drug Profile 93 GP-1001 - Drug Profile 94 GP-1002 - Drug Profile 95 GP-1681 - Drug Profile 96 GREFLU/VIE - Drug Profile 98 HAI-05 - Drug Profile 99 iHA-24 - Drug Profile 100 Influ-nRNA - Drug Profile 101 influenza (strain H5N1, H1N1) vaccine - Drug Profile 102 influenza [strain A/H5N1] vaccine - Drug Profile 103 influenza [strain A/H5N1] vaccine - Drug Profile 104 influenza [strain H5N1, H7N2, H9N2] virus like particle vaccine - Drug Profile 105 influenza [strain H5N1] (split virion) vaccine - Drug Profile 106 influenza [strain H5N1] vaccine - Drug Profile 107 influenza [strain H5N1] vaccine - Drug Profile 108 influenza [strain H5N1] vaccine - Drug Profile 109 influenza [strain H5N1] vaccine - Drug Profile 110 influenza [strain H5N1] vaccine - Drug Profile 112 influenza [strain H5N1] vaccine - Drug Profile 113 influenza [strain H5N1] vaccine - Drug Profile 114 influenza [strain H5N1] vaccine - Drug Profile 115 influenza [strain H5N1] vaccine - Drug Profile 116 influenza [strain H5N1] virus like particle vaccine + Glucopyranosyl Lipid A Adjuvant - Drug Profile 117 influenza [strain H5N1] virus like particles vaccine - Drug Profile 119
5
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile 121 influenza A vaccine - Drug Profile 122 influenza vaccine - Drug Profile 123 influenza vaccine - Drug Profile 124 influenza virus like particle vaccine - Drug Profile 126 Innate Immune Adjuvants - Drug Profile 127 INO-3510 - Drug Profile 128 IPS-07 series - Drug Profile 129 JNJ-872 - Drug Profile 130 KD-295 - Drug Profile 132 KIB-PCI - Drug Profile 133 M-001 - Drug Profile 134 MBX-2329 - Drug Profile 137 MBX-2546 - Drug Profile 139 MEDI-550 - Drug Profile 140 MG-1109 - Drug Profile 142 Monoclonal Antibodies to Inhibit H5 HA and H7 HA for Avian Infection - Drug Profile 144 Monoclonal Antibody to Inhibit Hemagglutinin for Influenza - Drug Profile 145 MVAH-5HA - Drug Profile 146 Myelo-001 - Drug Profile 147 NVINF-1 - Drug Profile 148 NVINF-2 - Drug Profile 150 OrniFlu - Drug Profile 151 PanBlok - Drug Profile 152 PDS-0102 - Drug Profile 154 PNSIA-28 - Drug Profile 155 PNSIA-49 - Drug Profile 156 6
PXVX-0103 - Drug Profile 157 rintatolimod - Drug Profile 159 S-033188 - Drug Profile 161 Small Molecules to Activate Sirtuin for Influenza - Drug Profile 162 Small Molecules to Inhibit Endonuclease for Flu - Drug Profile 163 STP-702 - Drug Profile 164 Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile 165 TCN-032 - Drug Profile 166 TVX-003 - Drug Profile 168 VAX-161 - Drug Profile 169 VGX-3400X - Drug Profile 170 VH-244 - Drug Profile 172 H5N1 Infection (Avian Influenza) - Recent Pipeline Updates 174 H5N1 Infection (Avian Influenza) - Dormant Projects 200 H5N1 Infection (Avian Influenza) - Discontinued Products 205 H5N1 Infection (Avian Influenza) - Product Development Milestones 206 Featured News & Press Releases 206 Appendix 213 Methodology 213 Coverage 213 Secondary Research 213 Primary Research 213 Expert Panel Validation 213 Contact Us 213 Disclaimer 214"
7
Read More http://www.idatainsights.com/reports-landing-page.php?id=173366/h5n1-infectionavian-influenza-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
8
9